Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 5 September 2007. doi:10.1136/adc.2006.104638
Archives of Disease in Childhood - Fetal and Neonatal Edition 2007;92:F503-F507
Copyright © 2007 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health.

REVIEW

Haematology of Down syndrome

David Webb1, Irene Roberts2, Paresh Vyas3

1 Department of Haematology, Great Ormond Street Hospital for Children, London, England
2 Department of Haematology, Hammersmith and St Mary’s Hospitals, Imperial College, London, England
3 Department of Haematology and MRC Molecular Haematology Unit, John Radcliffe Hospital and Weatherall Institute of Molecular Medicine, Oxford, England

Paresh Vyas, Department of Haematology and MRC Molecular Haematology Unit, John Radcliffe Hospital and Weatherall Institute of Molecular Medicine, Oxford OX3 9DU, England; paresh.vyas{at}imm.ox.ac.uk

ABSTRACT

Down syndrome is a common congenital disorder affecting ~1/1000 live births. Newborns and children with Down syndrome may present with many haematological problems. In addition, benign abnormalities of the blood count and blood film, which may manifest at any age, population-based and cancer-based registries and clinical trials suggest there is a ~12-fold increased risk of acute lymphoblastic leukaemia in the age group of 5–30 years that rises to ~40-fold in children younger than 5 years, and that there is a ~150-fold increased risk of acute myeloid leukaemia in children younger than 5 years. There is also a virtually unique predisposition to a transient neonatal leukaemia, known as transient abnormal myelopoiesis. Deaths from leukaemia, in part, account for the excess mortality associated with Down syndrome. This article reviews the clinical presentation and the progress made in the management of these disorders over the past decade. It also briefly considers the recent exciting scientific advances that have potential to transform management of leukaemia in children with Down syndrome and also have implications for management of childhood leukaemia more generally.

Abbreviations: ALL-DS, acute lymphoblastic leukaemia of Down syndrome; MDS, myelodysplastic phase; ML-DS, myeloid leukaemia of Down syndrome; TAM, transient abnormal myelopoiesis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Latest from ADC

 

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics

BMJ Careers - Latest Paediatrics and Paediatric Surgery Jobs

Paediatrics and Paediatric Surgery Jobs